This HTML5 document contains 63 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/wikipedia/
n24http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/AHFS/
n20http://linked.opendata.cz/resource/mesh/concept/
n14http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n8http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/pubchem-compound/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/kegg-drug/
n23http://bio2rdf.org/drugbank:
n9http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/pubchem-substance/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/national-drug-code-directory/
n26http://linked.opendata.cz/resource/drugbank/patent/
n6http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n18http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n19http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00538/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00538
rdf:type
n3:Drug
n3:description
Gadoversetamide is a gadolinium compound used as a contrast agent in magnetic resonance imaging (MRI), particularly imaging of the brain, spine and liver. It is marketed under the trade name OptiMARK.
n3:dosage
n15:271B41BA-363D-11E5-9242-09173F13E4C5
n3:group
investigational approved
n3:halfLife
Distribution 13.3 ± 6.8 (mean) minutes, elimination 103.6 ± 19.5 (mean) minutes.
n3:indication
Gadoversetamide is an MRI contrast agent used for MRI diagnostic procedures to provide increased enhancement and visualization of lesions of the brain, spine and liver, including tumors.
n3:manufacturer
n14:271B41B8-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00538 n23:DB00538
dcterms:title
Gadoversetamide
adms:identifier
n8:444013 n9:46504481 n12:0019-1177-02 n13:D01646 n21:392041 n22:DB00538 n24:PA164743703 n25:Gadoversetamide
n3:mechanismOfAction
Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. MR images are based primarily on proton density and proton relaxation dynamics. MR instruments are sensitive to two different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and T2 (spin-spin or transverse relaxation time). Paramagnetic agents contain one or more unpaired electrons that enhance the T1 and T2 relaxation rates of protons in their molecular environment. In MRI, visualization of normal and pathological brain, spinal and hepatic tissue depends in part on variations in the radio frequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in T2. When placed in a magnetic field, gadoversetamide shortens the T1 and T2 relaxation times in tissues where it accumulates. At the recommended dose, the effect is primarily on T1 relaxation time, and produces an increase in signal intensity (brightness). Gadoversetamide does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in CNS lesions that may have a normal blood-brain barrier (e.g., cysts, mature post-operative scars). Abnormal vascularity or disruption of the blood-brain barrier allows accumulation of gadoversetamide in lesions such as neoplasms, abscesses, and subacute infarcts.
n3:packager
n14:271B41B7-363D-11E5-9242-09173F13E4C5
n3:patent
n26:5130120
n3:routeOfElimination
The mean cumulative urinary excretion of gadoversetamide at 72 hours was approximately 93.5% for renal impaired patients and 95.8% for subjects with normal renal function
n3:synonym
Gadoversetamid Gadoversetamidum OptiMARK Gadoversetamida Gadoversetamide
n3:volumeOfDistribution
* 162 ± 25 mL/kg [normal subjects]
n10:hasAHFSCode
n17:36-68-00
n19:hasConcept
n20:M0291274
n3:IUPAC-Name
n4:271B41BF-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41C5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41C4-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41C1-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41C2-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41C3-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41BD-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41BB-363D-11E5-9242-09173F13E4C5 n4:271B41BE-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41BC-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:V08CA06
n3:H-Bond-Acceptor-Count
n4:271B41CB-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41CC-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41C6-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41C7-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41C9-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41C8-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41CA-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
131069-91-5
n3:category
n3:clearance
* 72 +/- 16.3 mL/hr/kg [healthy]
n3:containedIn
n18:271B41B9-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41D1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41D3-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41D4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41D0-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41CF-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41D2-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41C0-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41CD-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B41CE-363D-11E5-9242-09173F13E4C5